Shares of Daré Bioscience, Inc. (NASDAQ:DARE – Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.67 and traded as low as $3.32. Daré Bioscience shares last traded at $3.32, with a volume of 18,820 shares changing hands.
Wall Street Analysts Forecast Growth
DARE has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $72.00 target price on shares of Daré Bioscience in a report on Wednesday, May 15th. Brookline Capital Management raised shares of Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Wednesday, May 15th.
Get Our Latest Stock Report on DARE
Daré Bioscience Price Performance
Daré Bioscience (NASDAQ:DARE – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.12). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.52 million. During the same quarter in the prior year, the firm posted ($1.08) earnings per share. On average, research analysts expect that Daré Bioscience, Inc. will post -2.57 earnings per share for the current fiscal year.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Stories
- Five stocks we like better than Daré Bioscience
- 3 Stocks to Consider Buying in October
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Energy and Oil Stocks Explained
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What is a Bond Market Holiday? How to Invest and Trade
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.